Key Insights

Highlights

Treatment Research

20 treatments under study, led by Biospecimen Collection

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 2 (1)

Trial Status

Active Not Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT04539808Phase 2Active Not Recruiting

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

NCT06132087Not ApplicableActive Not Recruiting

PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy

Showing all 2 trials

Research Network

Common Treatments

  • Biospecimen Collection2
  • Losartan Potassium1
  • Distal Pancreatectomy1
  • Nab Paclitaxel1
  • Computed Tomography1

Active Sponsors

  • University of Southern California1
  • OHSU Knight Cancer Institute1
  • National Cancer Institute (NCI)1
  • Oregon Health and Science University1

Top Investigators

Related Conditions

  • Stage Iv Pancreatic Cancer American Joint Committee On Cancer V81
  • Stage 0 Pancreatic Cancer American Joint Committee On Cancer V81
  • Locally Advanced Pancreatic Adenocarcinoma1
  • Pancreatic Adenocarcinoma1
  • Stage I Pancreatic Cancer American Joint Committee On Cancer V81

Activity Timeline